Status:
TERMINATED
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Lead Sponsor:
Celgene
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with ...
Detailed Description
This is a test.
Eligibility Criteria
Inclusion
- Progressed on standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors, advanced unresectable colorectal cancer, or squamous cell carcinoma of the head and neck, or CD20-positive non-Hodgkin's lymphoma, or diffuse large B cell lymphoma, or follicular lymphoma
- Solid tumors must have at least one site of measurable disease as determined by RECIST v1.1
- Eastern cooperative oncology group performance status of 0 or 1
Exclusion
- High-grade lymphomas (Burkitt's or lymphoblastic)
- Has cancer with symptomatic central nervous system (CNS) involvement
- History of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 5 2024
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT03783403
Start Date
March 1 2019
End Date
August 5 2024
Last Update
September 19 2024
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 105
Birmingham, Alabama, United States, 35294
2
Local Institution - 101
Scottsdale, Arizona, United States, 85258
3
Local Institution - 112
Sacramento, California, United States, 95817
4
Rocky Mountain Cancer Centers, LLP [Aurora-COAU]
Aurora, Colorado, United States, 80012